Teva, mAbxience Strike Licensing Deal for Biosimilar Candidate Focused on Multiple Oncology Indications

Agreement comes as Teva aims to strengthen its biosimilar portfolio as part of its “Pivot to Growth” strategy.

Source link
#Teva #mAbxience #Strike #Licensing #Deal #Biosimilar #Candidate #Focused #Multiple #Oncology #Indications